A Non-interventional Study of immediate postoperative adjuvant hormonal treatment in high risk localised or locally advanced Chinese prostate cancer patients.
2 years PSA recurrence rate
18 Years +
Endpoint Classification: -
Intervention Model: -
Primary Purpose: -
Verified 01 May 2016 by AstraZeneca
No locations available
Localised with one of any high recurrence risk factors, or locally advanced Chinese prostate cancer patients confirmed histologically through radical prostatectomy either with laparoscopy or laparotomy within 1 month after surgery. Before the patient recruitment, the investigator has decided to prescribe immediate postoperative adjuvant hormonal treatment to the patient according to the Chinese routine practice.